Fig. 2From: Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 studyIxazomib dose-normalized AUC0–168 on day 1 (a) and day 15 (b) of cycle 1 in East Asian and Western patients. Box plots represent the 25th, 50th, and 75th percentiles; whiskers denote the 10th and 90th percentiles. East Asian patients received ixazomib in combination with lenalidomide–dexamethasone. Western patients received ixazomib as a single agent or in combination with lenalidomide–dexamethasoneBack to article page